Keyphrases
Sickle Cell Disease
96%
Pediatric Oncology
80%
Pediatric Patients
51%
Peripheral Quantitative Computed Tomography (pQCT)
51%
Childhood Cancer Survivors
51%
Density Change
48%
Spirometry
48%
Prednisolone
48%
Pediatric Leukemia
48%
Transcriptional Regulation
48%
Silent Carrier
48%
Subclone
48%
Acute Care
48%
Growing Rats
48%
Successful Treatment
48%
Alendronate
48%
Enzyme Gene
48%
Simulation Performance
48%
Angiotensin-converting Enzyme
48%
Tumor Suppressor
48%
Acute Lymphoblastic Leukemia
48%
Performance Assessment
48%
Resident Education
48%
Impulse Oscillometry
48%
Mixed-phenotype Acute Leukemia
48%
Densitometry
48%
Methotrexate
48%
Simulation Training
48%
State-based
48%
Structural Change
48%
Sirolimus
48%
Diagnostic Value
48%
Physical Activity Program
48%
Pilot Randomized Controlled Trial
48%
Fertility Preservation
48%
Decision Regret
48%
Leukemia
45%
Intervention Group
40%
Bone Mineral Density
36%
Coagulopathy
32%
Pediatric Residents
28%
Emotion Estimation
24%
Acute Myeloid Leukemia
24%
Perceived Challenges
24%
α-thalassemia
24%
Perceived Threat
24%
Pediatricians
24%
Evidence-based Care
24%
Pathogenicity
20%
Asthma Diagnosis
20%
Medicine and Dentistry
Childhood Cancer
100%
Sickle-Cell Disease
96%
Diagnosis
67%
Neonatal Infant
64%
Leukemia
60%
Randomized Controlled Trial
60%
Pediatrics Patient
51%
Alendronic Acid
48%
Prednisolone
48%
Oscillometry
48%
Emergency Care
48%
Spirometry
48%
Alpha-Thalassemia
48%
Simulation Training
48%
Vincristine
48%
Patient with Sickle Cell Disease
48%
Pediatric Acute Myeloid Leukemia
48%
Rapamycin
48%
Hemangioendothelioma
48%
Methotrexate
48%
Physical Activity
48%
Fertility Preservation
48%
Cancer in Young Adults
48%
Systematic Review
48%
Asthma
41%
Checklist
33%
Bleeding
32%
Thrombocytopenia
32%
Coagulopathy
32%
Pediatrics
31%
Bone Density
24%
Analysis of Variance
24%
Pediatrician
24%
Arm
24%
Health Care Cost
24%
Acute Myeloid Leukemia
21%
Malignant Neoplasm
16%
Neoplasm
16%
Blood Product
16%
Thigh
16%
Hemostat
16%
Vascular Anomaly
16%
Biopsy Technique
16%
Bronchodilating Agent
13%
Lung Function Test
13%
Forced Expiratory Volume
13%
End of Life Care
12%
Mediastinum Mass
12%
Neutropenia
12%